Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00550615 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: Dasatinib
DRUG: Dasatinib Maximum Tolerated Dose

Sponsor

University of Nebraska

Collaborators

[object Object]